I. Lipkin, MD - Professor

132 SCIENTIFIC SESSIONS September 9-12 | ------------------------------------------------------------------------ 152 H Symposium What’s New in Antiretroviral Therapy Tuesday, 8:30 a.m.–10:30 a.m. . . . . . . . . . . . . . . . . . . Room 130 UAN: 0391-9999-12-123-L04-P Conveners: Roy M. Gulick, MD - Professor of Medicine Weill Cornell Med. Coll., New York, NY. Joseph Eron, Jr., MD - Professor of Medicine Univ. of North Carolina, Chapel Hill, NC. Speakers: 8:30 a.m. 1185 Antiretroviral Therapy 2012: What to Start? Joel E. Gallant, MD, MPH - Professor of Medicine Epidemiology Johns Hopkins Univ. Sch. of Med., Baltimore, MD. 9:00 a.m. 1186 New Antiretrovirals and Novel Strategies for the Treatment of HIV-1 Infection Patrick G. Yeni, MD - Professor Hosp. Bichat-Claude Bernard and Xavier Bichat Med. Sch., Paris, France. 9:30 a.m. 1187 Pre-Exposure Prophylaxis PrEP for HIV-1: Where Have We Been and Where are We Going? Jared Baeten, MD, PhD - Associate Professor Univ. of Washington, Seattle, WA. 10:00 a.m. 1188 Top Papers in Antiretroviral Therapy: Including Key Presenta- tions from the 2012 International AIDS Conference Roy M. Gulick, MD - Professor of Medicine Weill Cornell Med. Coll., New York, NY. Objectives: Upon completion of this Symposium Session, the participant should be able to: Discuss several recommended initial antiretroviral regimens for the treat- ment of HIV-1 infection and identify potential patient types for which one regimen may be more suited than another; Summarize information of new antiretroviral agents and antiretroviral treatment strategies that are in development for the treatment of HIV-1 infection; Compare data from several large studies of pre-exposure prophylaxis stud- ies using antiretrovirals for the prevention of HIV infection and consider which at risk individuals may benefit from PrEP for HIV prevention; and Review the most important antiretroviral research studies that were published in 2012 or were presented at the 2012 International AIDS conference in Washington DC. Intended Audience: HIV clinicians including MD, pharmacists, pharmacol- ogists, physician extenders and other clinician, HIV clinical and translational scientists including those involved in all phases of antiretroviral research, virologists, and drug developers. Level: All Levels ------------------------------------------------------------------------ 153 L Symposium Dangerous Pets and Other Animals Tuesday, 8:30 a.m.–10:30 a.m. . . . . . . . . . . . . . . . . . . Room 102 UAN: 0391-9999-12-124-L04-P Conveners: Tara C. Smith, PhD - Assistant Professor Epidemiology, Univ. of Iowa, Iowa City, IA. David Aronoff, MD - Associate Professor Univ. of Michigan, Ann Arbor, MI. Speakers: 8:30 a.m. 1189 The Role of Bats in the Transmission of Dangerous Zoonotic Viruses Lin-Fa Wang, PhD - Professor CSIRO Australian Animal Hlth. Lab., Geelong, Australia. 9:00 a.m. 1190 Microbe Hunting: New Approaches to Pathogen Surveillance and Discovery

W. I. Lipkin, MD - Professor

Columbia Univ., New York, NY. 9:30 a.m. 1191 MRSA and Animals Tara C. Smith, PhD - Assistant Professor Univ. of Iowa, Iowa City, IA. 10:00 a.m. 1192 Once Bitten, Twice Shy: Animal Bites and Infectious Diseases David F. Looke, MD - Infectious Diseases Physician and Clinical Microbiologist Princess Alexandra Hosp., Univ. of Queensland, Brisbane, Australia. Objectives: Upon completion of this Symposium Session, the participant should be able to: Discuss how to diagnose zoonotic infections; Effectively treat infections related to animal bites; and Identify new concepts regarding the epidemiology of newly recognized zoonotic infections. Intended Audience: Clinicians, scientists, researchers, microbiologists, and public health physicians. Level: All Levels 133 TUESDAY SCIENTIFIC SESSIONS Final Program ------------------------------------------------------------------------ 154L, F Symposium What Every Clinician Should Know About Emerging New Antimicrobials Tuesday, 8:30 a.m.–10:30 a.m. . . . . . Esplanade Ballroom 305 UAN: 0391-9999-12-125-L04-P Conveners: M. Lindsay Grayson, MD - Professor Univ. of Melbourne, Austin Hlth., Melbourne, Australia. George M. Eliopoulos, MD - Professor of Medicine Beth Israel Deaconess Med. Ctr., Boston, MA. Speakers: 8:30 a.m. 1193 Fidaxomicin and Other Macrocyclic Antibiotics Kathleen Mullane, DO, PharmD - Associate Professor of Medicine Univ. of Chicago, Chicago, IL. 8:50 a.m. 1194 New Oxazolidinones, Including Tedizolid Torezolid, TR-700 George M. Eliopoulos, MD - Professor of Medicine Beth Israel Deaconess Med. Ctr., Boston, MA. 9:10 a.m. 1195 Ceftaroline: An Update Helen W. Boucher, MD, FACP - Associate Professor Tufts Med. Ctr., Boston, MA. 9:30 a.m. 1196 New Beta-LactamBeta-Lactamase Combinations Including Avibactam NKL104 and Tazobactam David M. Livermore, PhD - Professor Univ. of East Anglia, Norwich, United Kingdom. 9:50 a.m. 1197 Plazomicin ACHN-490 and Other Neoglycosides Karen Bush, PhD - Adjunct Professor Indiana Univ., Bloomington, IN. 10:10 a.m. Waiting for replacement Objectives: Upon completion of this Symposium Session, the participant should be able to: Discuss the new emerging antimicrobial agents; Recognize when these new agents may be of value in clinical practice; Assess how to safely use these new agents; and Identify the current development pathway for these new agents. Intended Audience: Clinicians, scientists, researchers, and microbiologists. Level: All Levels ------------------------------------------------------------------------ 155 P Symposium Update on Drug Resistance in Malaria Tuesday, 8:30 a.m.–10:30 a.m. . . . . . Esplanade Ballroom 310 UAN: 0391-9999-12-126-L04-P Conveners: Thomas E. Wellems, MD, PhD - Chief, LMVR NIAID, NIH, Bethesda, MD. Alan J. Magill, MD - Program Manager Defense Sci. Office DSO, Defense Advanced Res. Programs Agency DARPA, Arlington, VA. Speakers: 8:30 a.m. 1199 What Can We Learn from the History of Resistance to Anti- Malarial Drugs? Thomas E. Wellems, MD, PhD - Chief, LMVR NIAID, NIH, Bethesda, MD. 9:00 a.m. 1200 Emerging Artemisinin Resistance in Plasmodium falciparum Malaria Rick M. Fairhurst, MD, PhD - Clinical Tenure-Track Investigator NIAID, NIH, Bethesda, MD. 9:30 a.m. 1200a Selection of Malaria Parasites with Decreased Sensitivity to Artemisinin Partner Drugs Philip J. Rosenthal, MD - Professor San Francisco Gen. Hosp., San Francisco, CA. 10:00 a.m. 1201 Designing the Next Generation of Medicines for Malaria Control and Elimination Tim Wells, PhD - Chief Scientific Officer Med. for Malaria Venture, Geneva, Switzerland. Objectives: Upon completion of this Symposium Session, the participant should be able to: Describe the current global distribution of genotypic and phenotypic markers associated with drug resistance to malaria; Compare the difference between therapeutic failures and drug resistance; Recognize the technical and biologic difficulties in isolating and identifying the genetic correlates of acquired drug resistance in malaria; and Interpret genotypic and phenotypic data acquired in the laboratory and apply to treatment recommendations. Intended Audience: Graduate students, MsC, and PhD, Public Health ID residents and trainees, ID Fellows and MDS. Level: Intermediate 134 SCIENTIFIC SESSIONS September 9-12 | ------------------------------------------------------------------------ 156 C1 Slide Session Extended Spectrum ơ-Lactamases Tuesday, 8:30 a.m.–11:00 a.m. . . . . . . . . . . . . . . . . . . Room 121 UAN: 0391-9999-12-127-L04-P Moderators: Patrice Nordmann, MD - Professor Hosp. Bicetre, Le-Kremlin-Bicetre, France. Gian M. Rossolini, MD - Professor of Clinical Microbiology Siena Univ. Hosp., Siena, Italy. Objectives: Upon the completion of this Slide Session, the participant should be able to: Identify current epidemiology trend in emerging ESBLs; Discuss genetic vectors of ESBLs; and Understand the factors contributing to the spread of ESBLs. Presentations: 8:30 a.m. C1-1202 How to Detect Extended-Spectrum Beta-Lactamase- Producing Enterobacteriaceae: A New Paradigm

P. Nordmann, MD, PhD - Professor, L. Poirel, PhD - Associate Researcher,